Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corporation (NASDAQ: RLYB) is a clinical-stage biotechnology company whose news flow centers on the development of therapies for severe and rare diseases. Company press releases and SEC filings highlight progress across its pipeline, with particular emphasis on RLYB116, a differentiated C5 inhibitor being evaluated in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study designed to demonstrate complete and sustained complement inhibition with favorable tolerability.
Investors following RLYB news can expect regular updates on clinical milestones for RLYB116, including cohort dosing, interim data, and the program’s initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS), two hematologic conditions with significant unmet need. Rallybio also issues news on its preclinical programs, such as RLYB332, a long-acting monoclonal anti-matriptase-2 antibody for diseases of iron overload, and on the ENPP1 inhibitor program REV102 for hypophosphatasia (HPP), which originated from a joint venture with Recursion Pharmaceuticals.
RLYB news releases frequently cover financial results, cash runway guidance, and portfolio decisions, including the discontinuation of the RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) based on Phase 2 pharmacokinetic data. Corporate and transaction updates, such as the sale of Rallybio’s interest in REV102 to Recursion for equity, milestones, and potential royalties, as well as workforce and cost-structure changes, are also disclosed.
This news page aggregates these company-issued updates, earnings announcements, and material event disclosures, offering a centralized view of Rallybio’s clinical progress, strategic transactions, and capital position for those tracking RLYB stock and its rare disease pipeline.
Rallybio Corporation (NASDAQ: RLYB) announced that the first subjects have been dosed in the Phase 1 study of RLYB212, targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT). A proof-of-concept study is anticipated in Q3 2022. Additionally, they are set to initiate a Phase 1 study of RLYB116, a C5 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) and generalized Myasthenia Gravis (gMG), in Q1 2022. The company is also advancing an ENPP1 inhibitor with IND-enabling studies expected in Q2 2022, enhancing their commitment to developing therapies for severe and rare diseases.
Rallybio Corporation (Nasdaq: RLYB) reported promising results from its Phase 1/2 study of RLYB211, an anti-HPA-1a antibody aimed at preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The data showed RLYB211 effectively eliminated HPA-1a mismatched platelets within 7 days, demonstrating a significant advantage over placebo. The study maintains a focus on safety and tolerability, confirming no serious adverse events. Rallybio plans to advance to the next phase with RLYB212, a monoclonal antibody targeting the same condition, with data expected mid-2022.
Rallybio (NASDAQ: RLYB), a clinical-stage biotechnology company, announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 8:00 a.m. ET. The company will engage in a virtual fireside chat and conduct one-on-one meetings on the same day. A webcast of the presentation will be available on Rallybio’s website, with an archived replay accessible for 30 days post-event. Founded in January 2018, Rallybio aims to develop therapies for severe and rare diseases across various medical fields.
Rallybio Corporation (Nasdaq: RLYB), a biotech firm focused on developing therapies for severe and rare diseases, announced participation in the Jefferies London Healthcare Conference. A pre-recorded fireside chat will be accessible for on-demand viewing starting November 18, 2021, at 3:00 a.m. ET. Following the event, an archived version of the webcast will be available for 30 days. Rallybio aims to address rare diseases through its innovative product portfolio, supported by a team of experts in biopharma.
Rallybio Corporation (Nasdaq: RLYB) reported third-quarter 2021 results, highlighting ongoing development in its FNAIT franchise. The company initiated a natural history study aimed at assessing FNAIT risk among expectant mothers. RLYB211's Phase 1/2 trial data is expected in Q4 2021, while Phase 1 studies for RLYB212 and RLYB116 are anticipated in Q1 2022. Financially, R&D expenses were consistent at $5.0 million, G&A expenses surged to $5.0 million, and net loss rose to $10.2 million. Cash reserves stood at $187.0 million post-IPO.
Rallybio Corporation (Nasdaq: RLYB) completed its IPO, raising approximately $92.7 million. The company presented clinical proof-of-concept data for RLYB211, aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), and plans to initiate Phase 1 studies for RLYB212 and RLYB116 in Q1 2022. In Q2 2021, Rallybio reported a net loss of $11.1 million and R&D expenses increased to $6.8 million, driven by development costs for its pipeline programs. As of June 30, 2021, the company had $112.7 million in cash, not including IPO proceeds.
Rallybio Corporation (Nasdaq: RLYB) has successfully closed its initial public offering (IPO) of 7,130,000 shares at $13.00 each, raising approximately $92.7 million in gross proceeds. This includes the full exercise of underwriters' option for an additional 930,000 shares. The offering's registration statement became effective on July 28, 2021, with Jefferies, Cowen, and Evercore ISI as joint book-running managers. Rallybio focuses on developing therapies for severe and rare diseases and aims to advance its product portfolio, which targets various rare disease areas.
Rallybio Corporation has priced its initial public offering (IPO) of 6,200,000 shares at $13.00 each, aiming for gross proceeds of approximately $80.6 million. Trading on the Nasdaq Global Market under the ticker symbol RLYB is set to commence on July 29, 2021, with the offering expected to close on August 2, 2021, pending customary conditions. Underwriters have a 30-day option to purchase an additional 930,000 shares. Rallybio focuses on developing therapies for severe rare diseases and was established in January 2018.